PYXS is trading at $2.59, down 6.5%, as the stock undergoes a correction following a sharp 24.22% rally in the previous regular session.
- The decline appears to be driven by normal volatility and profit-taking in a thinly traded, speculative biotech name, with no new company-specific news or filings reported this morning.
- Market sentiment remains pressured by ongoing concerns regarding the company's cash runway and previous going-concern warnings.